Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.emc.2019.08.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
JCO Glob Oncol
January 2025
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil.
Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.
Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.
Uterine organoids reveal insights into epithelial specification and plasticity in development and disease.
Proc Natl Acad Sci U S A
February 2025
Department of Obstetrics, Gynecology, and Women's Health, University of Missouri, Columbia, MO 65211.
Understanding how epithelial cells in the female reproductive tract (FRT) differentiate is crucial for reproductive health, yet the underlying mechanisms remain poorly defined. At birth, FRT epithelium is highly malleable, allowing differentiation into various epithelial types, but the regulatory pathways guiding these early cell fate decisions are unclear. Here, we use neonatal mouse endometrial organoids and assembloid coculture models to investigate how innate cellular plasticity and external mesenchymal signals influence epithelial differentiation.
View Article and Find Full Text PDFTreatment approaches in advanced penile cancer: targeted therapies and immunotherapy.
Front Oncol
January 2025
Department of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or metastatic disease. With the emergence of immune checkpoint inhibitors and targeted therapies for specific genomic aberrations in the treatment of over a dozen other cancers, recent studies have sought to identify therapies other than chemotherapy in treating this uncommon cancer. Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.
View Article and Find Full Text PDFUnderstanding the vaginal microbiome among women with different genotypes of human papillomavirus infection in remote Andaman islands.
Front Cell Infect Microbiol
January 2025
Indian Council of Medical Research - Regional Medical Research Centre, Port Blair, Andaman and Nicobar Islands, India.
Background: Human papillomavirus (HPV) is a viral infection, and its acquisition and persistence are significantly influenced by the vaginal microbiota. Understanding and comparing the vaginal microbiome of HPV infected women in Andaman and Nicobar Islands is crucial.
Methods: The study involved collecting vaginal swabs and extracting DNA using the QIAamp DNA Minikit.
Objectives: An emerging concept in the chronic pain literature, high-impact chronic pain (HICP), refers to pain that occurs very frequently and results in major disruption of daily life. Previous epidemiologic investigations have noted that lower educational attainment, age, and race appear to be associated with the frequency of HICP, but condition-specific investigations of HICP have been less common.
Methods: Here we investigate HICP status and its clinical/demographic correlates in the Multidisciplinary Approach to the study of chronic Pelvic Pain research network Symptom Pattern Study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!